C
Cellares
Automated IDMO Smart Factories for industrial-scale cell therapy manufacturing
About Cellares
Cellares is a South San Francisco Integrated Development and Manufacturing Organization (IDMO) that industrializes cell therapy production with automated, closed-system manufacturing and quality control. Its Cell Shuttle platform runs end-to-end GMP cell therapy manufacturing while Cell Q automates in-process and release testing; together the company reports roughly 10× higher throughput and lower per-patient costs versus conventional CDMO footprints of similar scale. Cellares operates or is building Smart Factories in South San Francisco and Bridgewater, New Jersey, with facilities in Leiden (Netherlands) and Kashiwa (Japan), and has a $380 million global manufacturing agreement with Bristol Myers Squibb; the Cell Shuttle has received FDA Advanced Manufacturing Technology designation. In January 2026 Cellares raised $257 million in Series D financing co-led by BlackRock and Eclipse, with T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI and Gates Frontier among new investors, bringing total capital raised to about $612 million; company updates later cited ARK Invest joining and expanding the Series D (press reports $277M). Sources: Cellares 28 Jan 2026; company ARK update.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- South San Francisco, United States
- Employees
- 314
- Open positions
- 18
- Dealroom signal
- 89.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Tech for Biotech and Pharma, Rumoured $1B, Biotech and Pharma, Cell Therapy, biotech medtech and e-health
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2026 | $277M | $1.1B | Baillie Gifford · Willett Advisors · T. Rowe Price · Intuitive Ventures | ↗ |
| SERIES COther financing | Aug 2023 | $255M | $1B | Bristol-Myers Squibb · Decheng Capital · Eclipse Ventures · Willett Advisors | ↗ |
Growth signals
Latest recorded traffic for Cellares is 31K monthly website visits, up 10.7% over the last three months. Cellares's team grew 10.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Eclipse Ventures
EcoR1 Capital
8VC
Decheng Capital
Skyviews Life Science
Series B and later12 investors entered at this stage
Koch Disruptive Technologies
Bristol-Myers Squibb
Willett Advisors
DFJ Growth
BlackRock
Baillie Gifford
T. Rowe Price
Intuitive Ventures- GFGates Frontier
EDBI
ARK Invest
Duquesne Family Office
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cellares on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cellares’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.